Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion

Transfusion

Volumn 54, Issue 4, 2014, Pages 1037-1045

  Lescoutra Etchegaray, Nathalie ^a   Sumian, Chryslain ^b   Culeux, Audrey ^a   Durand, Valérie ^c   Gurgel, Patrick V ^d   Deslys, Jean Philippe ^c   Comoy, Emmanuel E ^c  

^a Macopharma   (France)

^b MacoPharma   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d ProMetic Life Sciences Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RESIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD FILTRATION; BLOOD SAFETY; BLOOD TRANSFUSION; BRAIN HOMOGENATE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HAMSTER; HUMAN; INCUBATION TIME; LEUKOREDUCED RED BLOOD CELL; NONHUMAN; PRION DISEASE; SCALE UP; VARIANT CREUTZFELDT JAKOB DISEASE;

ANIMALS; CRICETINAE; DECONTAMINATION; EQUIPMENT DESIGN; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; FILTRATION; HUMANS; LEUKAPHERESIS; MESOCRICETUS; MICROPORE FILTERS; PRION DISEASES; PRIONS;

EID: 84898913943     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12420     Document Type: Article

References (33)

1. Will RG,. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003; 66: 255-265. (Pubitemid 37173506)
2. Anderson RM, Donnelly CA, Ferguson NM, et al. Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996; 382: 779-788. (Pubitemid 26299555)
3. Donnelly CA, Ferguson NM, Ghani AC, et al. Implications of BSE infection screening data for the scale of the British BSE epidemic and current European infection levels. Proc Biol Sci 2002; 269: 2179-2190. (Pubitemid 35341903)
4. Smith PG, Bradley R,. Bovine spongiform encephalopathy (BSE) and its epidemiology. Br Med Bull 2003; 66: 185-198. (Pubitemid 37173502)
5. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-421. (Pubitemid 38210057)
6. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-529. (Pubitemid 39070413)
7. Hewitt PE, Llewelyn CA, Mackenzie J, et al. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. Vox Sang 2006; 91: 348. (Pubitemid 44720171)
8. Hewitt PE, Llewelyn CA, Mackenzie J, et al. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006; 91: 221-230. (Pubitemid 44337279)
9. Cervia JS, Sowemimo-Coker SO, Ortolano GA, et al. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease. Transfus Med Rev 2006; 20: 190-206. Review. (Pubitemid 43903606)
10. Bishop MT, Diack AB, Ritchie DL, et al. Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease. Brain 2013; 136 (Pt 4): 1139-1145.
11. Bishop MT, Hart P, Aitchison L, et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 2006; 5: 393-398.
12. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
13. Ironside JW,. Variant Creutzfeldt-Jakob disease: an update. Folia Neuropathol 2012; 50: 50-56.
14. Clewley JP, Kelly CM, Andrews N, et al. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. BMJ 2009; 338: b1442. doi: 10.1136/bmj.b1442.
15. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733-739. (Pubitemid 38961558)
16. Ironside JW, Bishop MT, Connolly K, et al. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 2006; 332: 1186-1188. Epub 2006 Apr 10. Erratum in: BMJ. 2006 Aug 26;333(7565):416. (Pubitemid 44365449)
17. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry-Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. [cited 2013 Sep 11]. Available from: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/default.htm
18. Gregori L, McCombie N, Palmer D, et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004; 364: 529-531. (Pubitemid 39070414)
19. Gregori L, Lambert BC, Gurgel PV, et al. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands. Transfusion 2006; 46: 1152-1161. (Pubitemid 44139489)
20. Gregori L, Gurgel PV, Lathrop JT, et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006; 368: 2226-2230. (Pubitemid 44959015)
21. Cahill MR, Murphy T, Khan M, et al. Phase I/II safety study of transfusion of prion-filtered red cell concentrates in transfusion-dependent patients. Vox Sang 2010; 99: 174-176.
22. Lasmézas CI, Deslys JP, Demaimay R, et al. Strain specific and common pathogenic events in murine models of scrapie and bovine spongiform encephalopathy. J Gen Virol 1996; 77: 1601-1609. (Pubitemid 26248677)
23. Herigstad MO, Gurgel PV, Carbonell RG,. Transport and binding characterization of a novel hybrid particle impregnated membrane material for bioseparations. Biotechnol Prog 2011; 27: 129-139.
24. Sowemimo-Coker S, Kascsak R, Kim A, et al. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter. Transfusion 2005; 45: 1839-1844. Erratum in: Transfusion. 2006 Feb;46(2):313. (Pubitemid 43971410)
25. Lacroux C, Bougard D, Litaise C, et al. Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission. Plos One 2012; 7: e42019.
26. Cancelas JA, Rugg N, Pratt PG, et al. Infusion of P-Capt prion-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation. Transfusion 2011; 51: 2228-2236.
27. Elebute MO, Choo L, Mora A, et al. Transfusion of prion-filtered red cells does not increase the rate of alloimmunization or transfusion reactions in patients: results of the UK trial of prion-filtered versus standard red cells in surgical patients (PRISM A). Br J Haematol 2013; 160: 701-708.
28. Hornsey VS, Casey C, McColl K, et al. Characteristics of prion-filtered red cells suspended in pathogen-inactivated plasma (MB treated or solvent-detergent treated) for neonatal exchange transfusion. Vox Sang 2011; 101: 28-34.
29. Wiltshire M, Thomas S, Scott J, et al. Prion reduction of red blood cells: impact on component quality. Transfusion 2010; 50: 970-979.
30. Murphy CV, Eakins E, Fagan J, et al. In vitro assessment of red-cell concentrates in SAG-M filtered through the Macopharma P-CAPT prion-reduction filter. Transfus Med 2009; 19: 109-116.
31. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83 (Pt 11): 2897-2905. (Pubitemid 35276989)
32. Brown P, Rohwer RG, Dunstan BC, et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810-816. (Pubitemid 28421640)
33. Brown P, Cervenáková L, McShane LM, et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-1178.